NOXXON Pharma N.V. (ALNOX.PA)

0.2658 -0.0020 (-0.75%) At close: 05:35PM CET

NOXXON Pharma N.V.

Max-Dohrn-Strasse 8-10
Berlin 10589
Germany
49 30 726247 0
https://www.noxxon.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 12

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Aram Mangasarian	CEO & Member of Management Board	488.62k	N/A	1970
Mr. Bryan Jennings	CFO & Director	N/A	N/A	N/A
Dr. Jarl Ulf Jungnelius M.D., Ph.D.	Sr. Medical Advisor & Member of Management Board	N/A	N/A	1951

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase IIa clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.

Corporate Governance

NOXXON Pharma N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.